Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXR: XR-BUP vs SL-BUP for OUD in Rural Settings
NCT06023459Phase 3Completed
- Start
- Oct 2024
- Primary completion
- Nov 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of buprenorphine in opioid use disorder (OUD) (2 arms). Primary endpoints: Number of urine drug screen (UDS) results negative for opioids, Feasibility of study implementation at 14 weeks and 1 more. Started Oct 2024; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06023459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06023459.